Evidence map›Paper›PMID 40733647›Full record

ReviewVaccines2025

COVID-19 Vaccine Timing and Co-Administration with Influenza Vaccines in Canada: A Systematic Review with Comparative Insights from G7 Countries.

Farah Al Hashimi, Sherif Eneye Shuaib, Nicola Luigi Bragazzi, Shengyuan Chen, Jianhong Wu

Abstract readReview
In one paragraph

Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Farah Al HashimiLaboratory for Industrial and Applied Mathematics (LIAM), York University, 4700 Keele St., Toronto, ON M3J 1P3, Canada.ORCID 0000-0002-1913-9550
Sherif Eneye ShuaibLaboratory for Industrial and Applied Mathematics (LIAM), York University, 4700 Keele St., Toronto, ON M3J 1P3, Canada.ORCID 0000-0001-9333-121X
Nicola Luigi BragazziLaboratory for Industrial and Applied Mathematics (LIAM), York University, 4700 Keele St., Toronto, ON M3J 1P3, Canada.ORCID 0000-0001-8409-868X
Shengyuan ChenDepartment of Mathematics and Statistics, York University, 4700 Keele St., Toronto, ON M3J 1P3, Canada.
Jianhong WuLaboratory for Industrial and Applied Mathematics (LIAM), York University, 4700 Keele St., Toronto, ON M3J 1P3, Canada.ORCID 0000-0003-0052-5336

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesDespite significant advancements in vaccine development and distribution, the optimal timing and integration of COVID-19 vaccination in Canada remain crucial to public health. As the SARS-CoV-2 virus continues to evolve, determining effective timing strategies for booster doses is necessary to sustain immunity, especially in high-risk populations. This systematic review aims to critically evaluate the timing and co-administration strategies of COVID-19 vaccines in Canada, comparing them with approaches in other G7 nations.

methodsThe review seeks to identify best practices to inform national vaccination policies, with a particular focus on synchronizing COVID-19 and seasonal influenza vaccinations. We systematically searched Scopus, PubMed, Medline, and Web of Science (17 August 2021 to 7 July 2024) using the PECOS framework. Two independent reviewers screened titles/abstracts, extracted key data on immunogenicity, efficacy, and safety, and performed a narrative synthesis on timing and co-administration outcomes.

resultsEvidence summarized across G7 countries reveals that most nations are converging on annual or flexible booster schedules tailored to high-risk groups, often aligning COVID-19 vaccination with influenza campaigns. Countries like Canada, the UK, and the US have integrated these efforts, while others maintain more independent or heterogeneous approaches. In addition, timely booster doses, whether administered annually or more frequently in high-risk settings, consistently reduce infection rates and hospitalizations.

conclusionsThese findings collectively support the continued evolution of COVID-19 vaccination programs toward integrated, seasonally aligned strategies. Future public health efforts can build on these lessons not only to sustain protection against SARS-CoV-2 but also to strengthen preparedness for other respiratory infections.

Indexed as

booster strategiesco-administrationCOVID-19public health interventionsrespiratory disease preventionseasonal vaccinesvaccination timing

Identifiers

PMID40733647
PMCPMC12297974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.